SLS Stock Summary and Trading Ideas (Sellas Life Sciences Group | NASDAQ:SLS)

SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.

Sellas Life Sciences Group trades on the NASDAQ stock market under the symbol SLS.

As of March 25, 2026, SLS stock price climbed to $5.33 with 4,098,737 million shares trading.

SLS has a beta of 0.71, meaning it tends to be less sensitive to market movements. SLS has a correlation of 0.02 to the broad based SPY ETF.

SLS has a market cap of $956.93 million. This is considered a Small Cap stock.

In the last 3 years, SLS traded as high as $6.14 and as low as $.50.

The top ETF exchange traded funds that SLS belongs to (by Net Assets): XBI, IWM, VTI, VXF, IWO.

SLS has outperformed the market in the last year with a return of +333.3%, while the SPY ETF gained +15.9%. In the last 3 month period, SLS beat the market returning +87.7%, while SPY returned -4.4%. However, in the most recent 2 weeks SLS has underperformed the stock market by returning -8.4%, while SPY returned -2.5%.

SLS support price is $4.66 and resistance is $5.33 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that SLS shares will trade within this expected range on the day.